Organon Kicks Off Partnering Strategy with Pfizer Deal

Hard times at drug division Organon have forced Akzo Nobel to cut costs and restructure. As part of this effort, the Dutch conglomerate has implemented an aggressive partnering strategy to maximize the value of its late-stage pharma pipeline. Its potential $370 million pact with Pfizer for the Phase II/III antipsychotic asenapine marks an impressive start, and underscores Akzo's commitment to rebuilding Organon.

Desperate times call for desperate measures. Or in the case of Dutch conglomerate Akzo Nobel NV 's ailing human pharmaceuticals division, Organon NV , they call for Pfizer Inc. 's marketing muscle.

In late October 2003 Organon announced a worldwide co-promotion deal for its novel atypical antipsychotic asenapine, which is entering Phase...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Global Vision

More from In Vivo